RT Journal Article
T1 Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis.
A1 Remuzgo-Martinez, Sara
A1 Rueda-Gotor, Javier
A1 Pulito-Cueto, Veronica
A1 Lopez-Mejias, Raquel
A1 Corrales, Alfonso
A1 Lera-Gomez, Leticia
A1 Perez-Fernandez, Raquel
A1 Portilla, Virginia
A1 Gonzalez-Mazon, Iñigo
A1 Blanco, Ricardo
A1 Exposito, Rosa
A1 Mata, Cristina
A1 Llorca, Javier
A1 Hernandez-Hernandez, Vanesa
A1 Rodriguez-Lozano, Carlos
A1 Barbarroja, Nuria
A1 Ortega-Castro, Rafaela
A1 Vicente, Esther
A1 Fernandez-Carballido, Cristina
A1 Martinez-Vidal, Maria Paz
A1 Castro-Corredor, David
A1 Anino-Fernandez, Joaquin
A1 Peiteado, Diana
A1 Plasencia-Rodriguez, Chamaida
A1 Galindez-Agirregoikoa, Eva
A1 Garcia-Vivar, Maria Luz
A1 Vegas-Revenga, Nuria
A1 Urionaguena, Irati
A1 Gualillo, Oreste
A1 Quevedo-Abeledo, Juan Carlos
A1 Castañeda, Santos
A1 Ferraz-Amaro, Ivan
A1 Gonzalez-Gay, Miguel A
A1 Genre, Fernanda
K1 Axial spondyloarthritis
K1 Biomarker
K1 Cardiovascular risk
K1 Disease severity
K1 Irisin
K1 Subclinical atherosclerosis
AB Patients with axial spondyloarthritis (axSpA) have a high disease burden mainly due to the rheumatic disease itself, and also exhibit accelerated atherosclerosis, that leads to a higher incidence of cardiovascular (CV) disease. Accordingly, the identification of biomarkers of CV risk and inflammation in axSpA patients is clinically relevant. In this sense, given the beneficial functions exerted by the adipomyokine irisin in processes related to CV disease and inflammation, our aim was to assess, for the first time, the role of irisin as a genetic and serological biomarker of subclinical atherosclerosis, CV risk and disease severity in axSpA patients. A large cohort of 725 Spanish patients with axSpA was included. Subclinical atherosclerosis (presence of plaques and abnormal carotid intima-media thickness values) was evaluated by carotid ultrasound. Four irisin polymorphisms (rs16835198 G/T, rs3480 A/G, rs726344 G/A, and rs1570569 G/T) were genotyped by TaqMan probes. Additionally, serum irisin levels were determined by ELISA. Low irisin levels were linked to the presence of plaques (p=0.002) and atherogenic index values ≥4 (p=0.01). Serum irisin were positively correlated with C-peptide levels (p2.1 (Odds Ratio (OR): 0.48 [0.28-0.83] and OR: 0.73 [0.57-0.92], respectively, p=0.01 in both cases). Additionally, the frequency of rs1570569 T allele was higher in these patients (OR: 1.46 [1.08-1.97], p=0.01). Furthermore, the GGGT haplotype was more frequent in patients with ASDAS values >2.1 (OR: 1.73 [1.13-2.66], p=0.01). Our results indicate that low serum irisin levels could be indicators of the presence of subclinical atherosclerosis, high CV risk and more severe disease in axSpA patients. In addition, irisin may also constitute a genetic biomarker of disease activity in axSpA.
PB Frontiers Research Foundation
YR 2022
FD 2022-06-08
LK http://hdl.handle.net/10668/20587
UL http://hdl.handle.net/10668/20587
LA en
NO Remuzgo-Martínez S, Rueda-Gotor J, Pulito-Cueto V, López-Mejías R, Corrales A, Lera-Gómez L, et al. Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis. Front Immunol. 2022 Jul 8;13:894171
DS RISalud
RD Apr 8, 2025